Truist Financial Cuts Inspire Medical Systems (NYSE:INSP) Price Target to $50.00

Inspire Medical Systems (NYSE:INSP) had its price objective decreased by Truist Financial from $64.00 to $50.00 in a research report sent to investors on Tuesday morning, MarketBeat reports. Truist Financial currently has a hold rating on the stock.

Several other equities research analysts also recently issued reports on the stock. Bank of America reaffirmed a “neutral” rating and set a $53.00 price target on shares of Inspire Medical Systems in a research note on Tuesday. Morgan Stanley set a $60.00 price target on shares of Inspire Medical Systems in a research note on Wednesday, February 18th. Piper Sandler downgraded shares of Inspire Medical Systems from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $85.00 to $55.00 in a research note on Tuesday. Jefferies Financial Group dropped their price target on shares of Inspire Medical Systems from $81.00 to $66.00 and set a “hold” rating on the stock in a research note on Thursday, February 12th. Finally, Evercore reaffirmed an “outperform” rating on shares of Inspire Medical Systems in a research note on Friday, February 27th. Four analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $85.00.

Inspire Medical Systems Trading Down 0.5%

Shares of INSP stock opened at $45.48 on Tuesday. The company’s fifty day simple moving average is $56.01 and its 200-day simple moving average is $78.97. Inspire Medical Systems has a 52 week low of $44.41 and a 52 week high of $161.88. The company has a market cap of $1.31 billion, a PE ratio of 10.13, a P/E/G ratio of 4.73 and a beta of 0.83.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The business had revenue of $204.58 million for the quarter, compared to the consensus estimate of $200.04 million. During the same quarter last year, the firm posted $0.10 EPS. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Equities research analysts expect that Inspire Medical Systems will post 0.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in INSP. Manning & Napier Advisors LLC acquired a new position in Inspire Medical Systems during the 3rd quarter worth $32,000. CWM LLC grew its holdings in Inspire Medical Systems by 216.1% during the 4th quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after acquiring an additional 242 shares in the last quarter. Havemeyer Place LP acquired a new position in Inspire Medical Systems during the 4th quarter worth $39,000. V Square Quantitative Management LLC acquired a new position in Inspire Medical Systems during the 4th quarter worth $40,000. Finally, Smartleaf Asset Management LLC grew its holdings in Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after acquiring an additional 205 shares in the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.